Inhibitors
Cat.No. | Name | Information |
---|---|---|
M1766 | PF-04217903 | PF-04217903 (PF-4217903) is a novel ATP-competitive small molecule inhibitor of c-Met kinases with the IC50 values from 3.1 nM to142 nM. |
M2080 | INCB28060 (Capmatinib) | INCB28060 is a novel inhibitor of c-MET kinase with IC50 of 0.13 nM. |
M1765 | Crizotinib (PF-02341066) | Crizotinib (PF-02341066) is a potent, orally bioavailable, ATP-competitive small-molecule inhibitor of c-Met kinase and ALK (anaplastic lymphoma kinase) with IC50 values to be 4 and 25 nM for C-Met and ALK resepectively. |
M1757 | XL-184 | XL184 is a small molecule inhibits multiple receptor tyrosine kinases, specifically MET and VEGFR2 with IC50 values of 0.035 and 1.8 nM for VEGFR2 and Met respectively. |
M10433 | Bozitinib (PLB-1001) | Bozitinib (PLB-1001; CBT-101) is a highly selective, blood-brain barrier permeable c-MET kinase inhibitor. |
M9521 | Glumetinib | Glumetinib, also known as SCC244, is a novel, potent and highly selective inhibitor of c-Met with an IC50 of 0.42 nM. |
M9158 | Dihexa | Dihexa is an orally active, blood-brain barrier-permeable angiotensin IV analog, exhibits high affinity binding hepatocyte growth factor (HGF) with a Kd of 65 pM. |
M9005 | NPS-1034 | NPS-1034 is a dual inhibitor of Axl and MET with IC50 values of 10.3 and 48 nM, respectively. |
M8928 | CEP-40783 | CEP-40783 (RXDX-106) is a potent, selective and orally available inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respectively. |
M6253 | Savolitinib (Volitinib) | Savolitinib (volitinib, AZD6094, HMPL-504) is a novel, potent, and selective MET inhibitor currently in clinical development in various indications, including PRCC. The IC50 values of this compound for c-Met and p-Met are 5 nM and 3 nM, respectively. It shows exquisite selectivity for c-Met over 274 kinase. |
M5310 | AMG 337 | AMG 337 is an oral, small molecule, ATP-competitive, highly selective inhibitor of the MET receptor. |
M5234 | S49076 | S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 values below 20 nmol/L. |
M4966 | DCC2701 | Altiratinib(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with a HGF antagonist in vitro. |
M3515 | MK-2461 | MK-2461 is a potent, multi-targeted inhibitor for c-Met(WT/mutants) with IC50 of 0.4-2.5 nM, less potent to Ron, Flt1; 8- to 30-fold greater selectivity of c-Met targets versus FGFR1, FGFR2, FGFR3, PDGFRβ, KDR, Flt3, Flt4, TrkA, and TrkB. |
M3396 | NVP-BVU972 | NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM. |
M2665 | EMD 1214063 | EMD 1214063 is a potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. |
M2080 | INCB28060 (Capmatinib) | INCB28060 is a novel inhibitor of c-MET kinase with IC50 of 0.13 nM. |
M1922 | MGCD265 | MGCD265 is a novel multitargeted receptor tyrosine kinase (RTK) inhibitor that targets the mesenchymal epithelial transition (c-Met) and the vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2, and VEGFR3). |
M1901 | Golvatinib | Golvatinib (E7050) is an orally bioavailable dual kinase inhibitor of c-Met and VEGFR-2 tyrosine kinases with potential antineoplastic activity. |
M1899 | PHA-665752 | PHA-665752 is a selective small molecule c-MET inhibitor (Ki of 4 nM, IC50 of 9 nM). |
M1890 | SU11274 | SU11274 is a selective c-Met inhibitor (IC50 = 0.01 μM in vitro). |
M1811 | Tivantinib (ARQ-197) | Tivantinib (ARQ 197) is a selective and oral small-molecule inhibitor of c-Met with a minimal IC50 value of 0.1 μM. |
M1793 | JNJ-38877605 | JNJ-38877605 is a small-molecule, ATP-competitive inhibitor of the catalytic activity of c-Met with an IC50 of 4 nM. |
M1777 | SGX523 | SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.